Bevacizumab-awwb

DRUG2 trials

Sponsors

ARCAGY/ GINECO GROUP, Amgen

Conditions

Metastatic Colorectal CancerOvarian Cancer

Phase 2

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

RecruitingNCT05183984

ARCAGY/ GINECO GROUPOvarian Cancer

Start: 2022-02-01End: 2032-02-01Target: 390Updated: 2026-04-13

Phase 3

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

RecruitingNCT06252649

AmgenMetastatic Colorectal Cancer

Start: 2024-07-17End: 2032-04-25Target: 450Updated: 2026-09-03

Related Papers

Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated <i>KRAS</i> G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).

Journal of Clinical Oncology2025-05-284 citations

A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with <i>KRAS</i> G12C–mutated metastatic colorectal cancer (CodeBreaK 301).

Journal of Clinical Oncology2025-01-272 citations